Add like
Add dislike
Add to saved papers

[Experimental investigation of CD133 as a putative marker of tumor-initiating cell in laryngeal carcinoma].

OBJECTIVE: To detect the expression of CD133 in human larynx tumor cell line, Hep-2 cell line and observe proliferation and differentiation ability of CD133+ groups in vitro.

METHODS: Immunocytochemical staining and flow cytometry were used to detect the expression of putative tumor-initiating cell marker CD133 in Hep-2 cell line, and the selective technique of immunomagnetic beads was applied to purify CD133 positive cells. CD133+ tumor cells were cultured and their ability of proliferation and differentiation were observed in vitro.

RESULTS: Only 3. 22% of cells in Hep-2 cell line expressed CD133. In serum-free RPMI1640, On days 3, 5 and 7, their UV absorption were 0. 320,0. 370 and 0. 558 respectively. Compared with CD133 - cells and control Hep-2 cells, CD133 + cells demonstrated increased proliferation capacity. The proportion of CD133+ cells decreased in culture as days passed. In twelve days of culture, the percentage of CD133+ cells decreased from 90. 88% to 4. 53 %.

CONCLUSIONS: CD133 was one of makers for tumor-initiating cell of human laryngeal carcinoma, Hep-2 cell line. Its identification would provide a helpful tool to investigate the tumorigenic process of human laryngeal carcinoma and to develop targeted therapies.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app